Quarterly ResultMay 7, 2026, 04:08 PM
4D Molecular Therapeutics Completes 4FRONT-1 Phase 3 Randomization; $458M Cash
AI Summary
4D Molecular Therapeutics reported Q1 2026 financial results and significant operational progress. The company completed randomization for its 4D-150 4FRONT-1 wet AMD Phase 3 trial with 523 patients, with topline data expected in H1 2027. Additionally, 4FRONT-2 enrollment is expected to complete in H2 2026, and a global Phase 3 trial for DME is set to begin in Q3 2026. The company ended Q1 with $458 million in cash, cash equivalents, and marketable securities, projected to fund operations into the second half of 2028, despite a net loss of $68.8 million for the quarter.
Key Highlights
- 4D-150 4FRONT-1 wet AMD Phase 3 trial randomization completed with 523 patients.
- Topline data for 4FRONT-1 expected in H1 2027; 4FRONT-2 enrollment completion in H2 2026.
- Cash, cash equivalents, and marketable securities totaled $458 million as of March 31, 2026.
- Existing cash expected to fund current operating plan into the second half of 2028.
- Q1 2026 collaboration and license revenue was $3.0 million, up from $0.014 million in Q1 2025.
- Q1 2026 R&D expenses increased to $65.0 million from $40.7 million in Q1 2025.
- Q1 2026 net loss was $68.8 million, compared to a net loss of $48.0 million in Q1 2025.